GLOBAL ENDOMETRIAL ABLATION MARKET GAME CHANGER
OCON’S SEAD™ – currently in Phase II Clinical Studies – offers a disposable, point of care therapy for abnormal uterine bleeding (AUB) and/or heavy menstrual bleeding – a far more comfortable and cost effective alternative for hundreds of thousands of women per year who opt to increase their quality of life.
14 – 25% of women
of reproductive age
are affected by AUB
costs of AUB in the US
for OBGYN visit
disruptive to sex life
period is heaviest
42% of women suffer
due to heavy periods
The Solution - The SEAD™
The SEAD™ is an innovative intrauterine drug delivery technology for women with abnormal uterine bleeding and/or heavy menstrual bleeding. The current standard of care (global endometrial ablation) is considered invasive, burdensome, debilitating, and costly and may result in uterine wall adhesions and even a hysterectomy.Current global ablation technologies currently in use require expensive capital equipment, extensive physician training, general anesthesia & hospitalization and cause high indirect costs and usually pain to women. The SEAD™ is a market game-changer through simplicity, cost-effectiveness, and new and innovative yet gentle “substance-derived ablation” technology. The SEAD™ is nearly pain-free2 and efficacious to reduce bleeding and increase the quality of life.
THE SEAD™ VALUE PROPOSITION:
- Highly cost effective: <1/2 compared to current treatments.
- Less invasive for women: pain-free2 and no need for hospitalization or general anesthesia
- A 30 minute in-office procedure: as easy, quick and painless as an IUD insertion.
- Short learning curve for the physicians compared to current options.
- Overcomes problems of uterine size and/or shape limitations.
The SEAD™ has the potential of becoming a strong and attractive choice of therapy in the worldwide GEA market through its simplicity, cost effectiveness and new and innovative yet gentle “substance-based Ablation” technology.
2 ongoing Phase II Clinical Studies, OCON Medical Ltd.
3 Phase I Clinical Study, OCON Medical Ltd.